1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Strong PhII data in triglyceride reduction attracts partners to Essentialis

 
• By Mandy Jackson

Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.

Essentialis Inc. is in discussions with partners and potential acquirers as its moves into Phase III clinical trials for diazoxide choline controlled-release tablets, or DCCR, a drug that may cause dramatic reductions in triglyceride levels for high-risk patients who already are taking cholesterol-lowering medications.

DCCR is a potassium channel agonist is a proprietary crystalline salt of diazoxide, an old vasodilator that has been used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapeutic Category

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.